Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Posted on by

Lancet Infectious Diseases
Apr 2022 Volume 22 Number 4p 427-562, e101-e127
https://www.thelancet.com/journals/laninf/issue/current

 

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
Gang Zeng, et al.